Neuroblastoma Recurrent Clinical Trials in Memphis, Tennessee

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma